How Does MFN Pricing Work Within TrumpRx?

With the launch of TrumpRx earlier this year, Americans got their first taste of how the administration is attempting to implement its most favored nation (MFN) pricing policies. Lindsay Bealor Greenleaf, head of market access policy strategy at ADVI, spoke with Pharmaceutical Executive about the current state of MFN and how the industry expects it to impact operations as more of the policies come online.

Pharmaceutical Executive: How does MFN pricing work within TrumpRx?
Lindsay Bealor Greenleaf: The two are certainly related, but I view them differently. One thing to point out is that the Trump RX website where patients can go is basically a direct-to-patient program. It's also a place where patients, whether or not they're getting access to a drug in a direct to patient format, can also have access to coupons and discounts.

The website is live. There's over 40 drugs that are on there. I think it's off to a great start, and it's helping a lot of patients. The launch of Trump RX coincided with a number of the MFN deal announcements that we had at the end of 2025, so when I think of Trump RX and MFN pricing, a lot of the prices that are on Trump RX do correspond to what may be an MFN price for a given drug, but not necessarily either.

It's meant to be a bigger, broader program focused on how to get patients access to the lowest cash pay price or greatest, coupon or discount that they can access. It will be a more seamless experience: go to one website, one stop shop, that sort of thing. MFN pricing overlaps, but it’s not necessarily a perfect correlation for all the drugs on TrumpRx.